Lymphoma treatment gains conditional approval in Europe
Roche's Polivy, or polatuzumab vedotin, an antibody-drug conjugate used in combination with bendamustine plus MabThera, or rituximab, received conditional approval from the European Commission to treat adults with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for a hematopoietic stem cell transplant. Seeking Alpha (1/21)
Read full article now.
Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!